Table 3A.
Top 20 key nodes in the network analysis of the IMI NDD portfolio: Including EFPIA partners.
| Organization (Country) | Type | Projects (N) | Betweenness | Degree |
|---|---|---|---|---|
| Janssen Pharmaceutica (BE) | EFPIA | 13 | 1,437 | 197 |
| UCB Biopharma (BE) | EFPIA | 7 | 1,068 | 164 |
| Pfizer (UK) | EFPIA | 7 | 1,022 | 177 |
| Novartis (BE) | EFPIA | 9 | 928 | 140 |
| AstraZeneca (UK) | EFPIA | 5 | 870 | 108 |
| Sanofi Aventis (FR) | EFPIA | 7 | 847 | 149 |
| Eli Lilly (UK) | EFPIA | 8 | 807 | 132 |
| Erasmus Medical Center (NL) | Academic | 7 | 679 | 148 |
| Biogen (UK) | EFPIA | 5 | 617 | 117 |
| Merck Sharp Dohme (BE) | EFPIA | 4 | 568 | 126 |
| F Hoffmann La Roche (SUI) | EFPIA | 7 | 515 | 153 |
| Takeda (UK) | EFPIA | 6 | 513 | 130 |
| H Lundbeck (DK) | EFPIA | 7 | 502 | 109 |
| Abbvie (FR) | EFPIA | 5 | 465 | 101 |
| Stichting VUMC (NL) | Academic | 7 | 458 | 130 |
| Kings College London (UK) | Academic | 5 | 417 | 101 |
| University of Cambridge (UK) | Academic | 5 | 389 | 132 |
| Academisch Ziekenhuis Leiden (NL) | Academic | 4 | 375 | 100 |
| Alzheimer Europe (LU) | Patient/carer organization | 7 | 366 | 113 |
| Amgen (SUI) | EFPIA | 3 | 365 | 111 |